Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.19 -4.4%	$2.27	$0.95 ▼ $2.85	$20.56M	0.13	149,129 shs	120,979 shs
EPIX ESSA Pharma	$1.92	$1.79	$1.40 ▼ $7.88	$85.23M	1.55	387,194 shs	680,796 shs
QNTM Quantum Biopharma	$22.35 -3.9%	$22.27	$2.70 ▼ $38.25	$67.60M	0.71	191,111 shs	123,352 shs
VXRT Vaxart	$0.36 -2.5%	$0.44	$0.26 ▼ $1.07	$82.41M	1.12	3.08 million shs	319,475 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	-4.37%	-7.59%	+0.92%	+2.82%	-12.40%
EPIX ESSA Pharma	0.00%	+1.05%	+2.67%	+12.28%	-57.62%
QNTM Quantum Biopharma	-3.87%	-14.07%	+15.74%	+118.05%	+2,234,999,900.00%
VXRT Vaxart	-6.37%	-7.83%	-3.51%	-28.73%	-39.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	3.7876 of 5 stars	3.5	2.0	0.0	3.4	3.3	0.0	0.6
EPIX ESSA Pharma	1.4287 of 5 stars	1.0	3.0	0.0	0.0	2.3	3.3	1.3
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	3.051 of 5 stars	3.5	5.0	0.0	0.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	3.00	Buy	$10.00	356.62% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	4.17% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A
VXRT Vaxart	3.00	Buy	$2.00	455.56% Upside

Current Analyst Ratings Breakdown

Latest AYTU, QNTM, EPIX, and VXRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81M	0.24	N/A	N/A	$4.64 per share	0.47
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A
VXRT Vaxart	$47.40M	1.74	N/A	N/A	$0.26 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-21.25%	-20.72%	8/18/2025 (Estimated)
QNTM Quantum Biopharma	-$14.20M	-$14.02	N/A	N/A	N/A	N/A	-270.22%	-131.87%	N/A
VXRT Vaxart	-$66.95M	-$0.27	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	N/A

Latest AYTU, QNTM, EPIX, and VXRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q3 2025	EPIX ESSA Pharma	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/6/2025	Q2 2025	QNTM Quantum Biopharma	-$0.17	-$3.23	-$3.06	-$3.23	$2.89 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
EPIX ESSA Pharma	N/A	67.15	67.15
QNTM Quantum Biopharma	N/A	0.78	0.95
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
EPIX ESSA Pharma	75.12%
QNTM Quantum Biopharma	1.24%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
EPIX ESSA Pharma	15.50%
QNTM Quantum Biopharma	8.53%
VXRT Vaxart	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A
VXRT Vaxart	120	228.92 million	222.37 million	Optionable

AYTU, QNTM, EPIX, and VXRT Headlines

Recent News About These Companies

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

August 13 at 10:05 PM | seekingalpha.com

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

August 13 at 6:26 PM | zacks.com

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

August 13 at 5:25 PM | reuters.com

Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's Why

August 7, 2025 | marketbeat.com

Vaxart (VXRT) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Vaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split Proposal

July 31, 2025 | quiverquant.comQ

Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's Why

July 29, 2025 | marketbeat.com

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

July 24, 2025 | globenewswire.com

Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?

July 19, 2025 | marketbeat.com

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

July 8, 2025 | financialpost.comF

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, QNTM, EPIX, and VXRT Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.19 -0.10 (-4.37%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.20 +0.01 (+0.46%)

As of 08/14/2025 07:57 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

ESSA Pharma NASDAQ:EPIX

$1.92 0.00 (0.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.91 -0.01 (-0.52%)

As of 08/14/2025 07:56 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Quantum Biopharma NASDAQ:QNTM

$22.35 -0.90 (-3.87%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$22.79 +0.44 (+1.97%)

As of 08/14/2025 07:39 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Vaxart NASDAQ:VXRT

$0.36 -0.01 (-2.54%)

As of 08/14/2025 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time